1. Hu, C. S. Wu, Q. H. & Hu, D. Y. Cardiovascular, diabetes, and cancer strips: evidences, mechanisms, and classifications. J. Thorac. Dis. 6, 1319-1328 (2014).
2. Hu, C. S. & Tkebuchava, T. SEEDi1.0-3.0 strategies for major noncommunicable diseases in China. J. Integr. Med. 15, 265-269 (2017).
3. Vidal-Petiot, E. et al. Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. Eur. Heart. J. 39, 3855-3863 (2018).
4. Yang, C. et al. Prevalence and treatment of hypertension in China: impacts of 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline. Sci. Bull. 63, 488-493 (2018).
5. Chen, W. et al. Cancer statistics in China, 2015. CA. Cancer. J. Clin. 66, 115-132 (2016).
6. Wu, D. et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature 559, 637-641 (2018).
7. Ohkuma, T., Peters, S. A. E. & Woodward, M. Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events. Diabetologia 61, 2140-2154 (2018).
8. Engle, D. D. et al. The glycan CA 19-9 promotes pancreatitis and pancreatic cancer in mice. Science 364, 1156-1162 (2019).
9. Melander, O. et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 308, 1469-1475 (2012).
10. Brainstorm Consortium. Anttila, V. et al. Analysis of shared heritability in common disorders of the brain. Science 360, eaap8757 (2018).
11. Scott, R. A. et al. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronaryheartdisease. Sci. Transl. Med. 8, 341ra76 (2016).
12. Liu, H. H. et al. Impacts of Prediabetes Mellitus Alone or Plus Hypertension on the Coronary Severity and Cardiovascular Outcomes. Hypertension 71, 1039-1046 (2018).
13. Echouffo-Tcheugui, J. B. et al. Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. Eur. Heart. J. 39, 2376-2386 (2018).
14. Tobias, D. K. et al. Association of History of Gestational Diabetes With Long-term Cardiovascular Disease Risk in a Large Prospective Cohort of US Women. JAMA. Intern. Med. 177, 1735-1742 (2017).
15. O'Donovan, G., Lee, I. M., Hamer, M. & Stamatakis, E. Association of "Weekend
Warrior" and Other Leisure Time Physical Activity Patterns With Risks for All-Cause, Cardiovascular Disease, and Cancer Mortality. JAMA. Intern. Med. 177, 335-432 (2017).
16. Sattar, N. et al. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks. Circulation 139, 2228-2237 (2019).
17. Rawshani, A. et al. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and CardiovascularOutcomes in Type 1 Diabetes Mellitus. Circulation 139, 1900-1912 (2019).
18. Wild, S. H. et al. Scottish Diabetes Research Network Epidemiology Group. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2Diabetesand Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes. Care. 41, 341-347 (2018).
19. Koene, R. J., Prizment, A. E., Blaes, A. & Konety, S. H. Shared risk factors in
cardiovascular disease and cancer. Circulation 133, 1104-1114 (2016).
20. Tu, H. et al. Cancer risk associated with chronic diseases and disease markers: prospective cohort study. BMJ 360, k134 (2018).
21. Conrad, N. et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 391, 572-580 (2018).
22. Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing,
cardiovascular disease, and frailty. Nat. Rev. Cardiol. 15, 505-522 (2018).
23. Hu, F. B. et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N. Engl. J. Med. 345, 790-797 (2001).
24. Bao, Y. et al. Association of nut consumption with total and cause-specific mortality. N. Engl. J. Med. 369, 2001-2011 (2013).
25. Nielsen, S. F., Nordestgaard, B. G. & Bojesen, S. E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792-1802 (2012).
26. Fernández-Solà, J. Cardiovascular risks and benefits of moderate and heavy
alcohol consumption. Nat. Rev. Cardiol. 12, 576-587 (2015).
27. Zheng, Y. et al. Associations of Weight Gain From Early to Middle Adulthood With Major Health Outcomes Later in Life. JAMA 318, 255-269 (2017).
28. Hu, C. Grants supporting research in China. Eur. Heart. J. 39, 2342-2344 (2018).
29. Hu, C. S. et al. A novel management program for hypertension. Cardiovasc. Diagn. Ther. 5, 316-322 (2015).
30. Hu, C., Tkebuchava, T. & Hu, D. Managing acute myocardial infarction in China. Eur. Heart. J. 40, 1179-1181 (2019).
31. Hu, C. S., Wu, Q. H., Hu, D. Y. & Tkebuchava, T. Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come. Chronic. Dis. Transl. Med. 5, 75-88 (2018).
32. Hu, C. S. A comprehensive strategy for managing arrhythmogenic right ventricular cardiomyopathy. Turk. Kardiyol. Dern. Ars. 48, 88-95 (2020).
33. Hu, C. S. Intervention of RT-ABCDEF for cancer. Croat. Med. J. 60, 55-57 (2019).
34. Morris, S. A. & Daley, G. Q. A blueprint for engineering cell fate: current technologies to reprogram cell identity. Cell. Res. 23, 33-48 (2013).
35. Infusino, G. A. & Jacobson, J. R. Endothelial FAK as a therapeutic target in disease. Microvasc. Res. 83, 89-96 (2012).
36. Lean, M. E. et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 391, 541-551 (2018).
37. Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107-113 (2017).
38. Hu, C. S. Analysis of COVID-19 Cases and Public Measures in China. SN. Compr.Clin. Med. 2, 1306-1312 (2020).
39. Shi, S. et al. Characteristics and Clinical Significance of Myocardial Injury in Patients With Severe Coronavirus Disease 2019. Eur. Heart. J. 41, 2070-2079 (2020).
40. Guzik, T. J. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 116, 1666-1687 (2020).
41. Evans, P. C. et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc. Res. 116, 2177-2184 (2020).
42. Ma, L. Y. et al. China cardiovascular diseases report 2018: an updated summary. J. Geriatr. Cardiol. 17, 1-8 (2020).
43. Toya, T. et al. Assessment of peripheral endothelial function predicts future risk of solid-tumor cancer. Eur. J. Prev. Cardiol. 27, 608-618 (2020).
44. Caro-Codón, J. et al. CARDIOTOX registry investigators. Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur. J. Prev. Cardiol. zwaa034 (2020).
45. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer. J. Clin. 71, 209-249 (2021).
46. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA. Cancer. J. Clin. 70, 7-30 (2020).
47. Zhang, S. et al. Cancer incidence and mortality in China, 2015. J. National. Cancer. Center. 1, 2-11 (2021). https://doi.org/10.1016/j.jncc.2020.12.001.
48. Murray, E., Tomaszewski, M. & Guzik, T. J. Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications. Cardiovasc. Res. 116, e87-e89 (2020).
49. Xiang, D. et al. Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China. J. Am. Coll. Cardiol. 76, 1318-1324 (2020).
50. Han, Y. et al. CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic. Circulation 141, e810-e816 (2020).